A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE: The therapeutic effects of 4-aminopyridine (4AP) were investigated in a randomized, double-blind, crossover trial in 10 subjects with familial episodic ataxia with nystagmus. METHODS: After randomization, placebo or 4AP (5 mg 3 times daily) was administered for 2 3-month-long treatment periods separated by a 1-month-long washout period. The primary outcome measure was the number of ataxia attacks per month; the secondary outcome measures were the attack duration and patient-reported quality of life (Vestibular Disorders Activities of Daily Living Scale [VDADL]). Nonparametric tests and a random-effects model were used for statistical analysis. RESULTS: The diagnosis of episodic ataxia type 2 (EA2) was genetically confirmed in 7 subjects. Patients receiving placebo had a median monthly attack frequency of 6.50, whereas patients taking 4AP had a frequency of 1.65 (p = 0.03). Median monthly attack duration decreased from 13.65 hours with placebo to 4.45 hours with 4AP (p = 0.08). The VDADL score decreased from 6.00 to 1.50 (p = 0.02). 4AP was well-tolerated. CONCLUSIONS: This controlled trial on EA2 and familial episodic ataxia with nystagmus demonstrated that 4AP decreases attack frequency and improves quality of life. LEVEL OF EVIDENCE: This crossover study provides Class II evidence that 4AP decreases attack frequency and improves the patient-reported quality of life in patients with episodic ataxia and related familial ataxias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Balint, B., Vincent, A., Meinck, H.-M., Irani, S. R., & Bhatia, K. P. (2018) · Brain · doi:10.1093/brain/awx189 · Cited by 203
“…and autoimmune neurology where 4-aminopyridine has proved beneficial in two disorders affecting P/Q type voltage-dependent calcium channels: episodic ataxia type 2 due to P/Q calcium channel gene mutations and Lambert-Eaton syndrome due to P/Q calcium channel autoantibodies (Strupp et al., 2011).”
BackgroundMutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia
Schwarz, N., Hahn, A., Bast, T., Müller, S., Löffler, H., Maljevic, S., Gaily, E., Prehl, I., Biskup, S., Joensuu, T., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-015-7984-0 · Cited by 95
Hedrich, U. B. S., Lauxmann, S., Wolff, M., Synofzik, M., Bast, T., Binelli, A., Serratosa, J. M., Martínez-Ulloa, P., Allen, N. M., King, M. D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4957 · Cited by 87
“4AP has been shown to be effective in small but well-designed clinical controlled trials in patients with downbeat nystagmus and episodic ataxia type 2 (16-18), as well as in some other patients with ataxia (19, 20).”
Background
Metadata
- Authors
- Strupp, M., Kalla, R., Claassen, J., Adrion, C., Mansmann, U., Klopstock, T., Freilinger, T., Neugebauer, H., Spiegel, R., Dichgans, M., Lehmann-Horn, F., Jurkat-Rott, K., Brandt, T., Jen, J. C., & Jahn, K.
- Venue
- Neurology
- Published
- 2011-07-19
- Volume
- 77
- Issue
- 3
- Pages
- 269-275
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2034395914
- Cited by
- 210
- References
- 0
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. https://app.cochat.ai/papers/10.1212/wnl.0b013e318225ab07
- The paper
- Strupp, M., Kalla, R., Claassen, J., Adrion, C., Mansmann, U., Klopstock, T., Freilinger, T., Neugebauer, H., Spiegel, R., Dichgans, M., Lehmann-Horn, F., Jurkat-Rott, K., Brandt, T., Jen, J. C., & Jahn, K. (2011). A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. https://doi.org/10.1212/wnl.0b013e318225ab07
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.